 |
| Global Interstitial Lung Disease Market Size |
Interstitial lung diseases (ILDs) refer to a large group of diffuse parenchymal lung diseases that affect the interstitium, or tissues and spaces around the air sacs (alveoli) of the lungs. The common symptoms include shortness of breath, a dry cough, and fatigue. ILDs can affect people of any age, however, the condition usually develops in middle-aged or older adults. The increasing pollution levels and rising global geriatric population, which are highly susceptible to ILDs, are major factors driving the growth of the interstitial lung disease market.
The global
Interstitial Lung Disease Market is estimated to be valued at US$ 1790.83 Mn in 2023 and is expected
to exhibit a CAGR of 6.5% over the
forecast period 2023 to 2030, as highlighted in a new report published by
Coherent Market Insights.
Market key trends:
The rising pollution levels worldwide have increased incidences of lung
diseases like chronic obstructive pulmonary disease (COPD) and asthma. The
toxic dust and gases inhaled aggravate lung conditions and sometimes lead to
pulmonary fibrosis or ILDs. According to some estimates, air pollution causes
around 4.2 million premature deaths globally every year. The increasing
pollution levels have propelled the demand for effective ILD therapeutics
globally. Pharmaceutical firms are expanding their R&D efforts to develop
novel therapies for better treatment outcomes and management of interstitial
lung diseases.
Segment
Analysis
The global interstitial lung disease market is dominated by idiopathic
pulmonary fibrosis segment, which accounts for over 35% share. Idiopathic
pulmonary fibrosis is the most common type of interstitial lung disease where
the lung tissue becomes thickened and scarred. The exact cause of idiopathic
pulmonary fibrosis is unknown but cigarette smoking increases the risk of
developing the disease. With no known cause and progressive scarring of lung
tissue, idiopathic pulmonary fibrosis has poor prognosis.
Key Takeaways
The Global
Interstitial Lung Disease Market Size is expected to witness high growth. The market
is estimated to reach US$ 3510.43 Mn by 2030 from US$ 1790.83 Mn in 2023, expanding at a CAGR of 6.5% during the forecast period.
Regional analysis
North America accounts for the largest share in the global interstitial lung
disease market supported by majority of the key players located in the region
and subsequent focus on R&D to develop new treatment options. The presence
of advanced healthcare facilities and growing awareness about lung diseases
also attribute to the strong position of North America. Asia Pacific is
expected to witness the fastest growth during the forecast period owing to
large patient pool in countries like China & India, improving healthcare
infrastructure, and rising healthcare expenditure.
Key players
Key players operating in the interstitial lung disease market are MSD (Merck),
Liminal Biosciences, Glenmark Pharma, J.B. Chemicals & Pharmaceuticals,
Boehringer Ingelhim International GmbH, F. Hoffmann-La Roche Ltd, Inc., and
Cipla. MSD (Merck) leads the market with its blockbuster drug Esbriet® approved
for idiopathic pulmonary fibrosis treatment. Liminal Biosciences and Glenmark
Pharma are also actively involved in R&D and clinical trials for developing
new treatment alternatives.
Get More Insights On This Topic: https://www.ukwebwire.com/interstitial-lung-disease-market-overview/